Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

ANKARA, TURKEY / ACCESSWIRE / September 25, 2024 / GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, ...

The FDA has already approved Zoryve cream (0.3% and 0.15%) for plaque psoriasis and atopic dermatitis in adults and children ...

Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Does your hair's length affect how you take care of, maintain, and stop scalp psoriasis from returning? Let's talk about it.

In this edition of The People's Pharmacy, Joe and Teresa Graedon also hear from a reader wondering about COVID-19-induced insulin resistance.

Access to adequate care for psoriasis is inconsistent across Europe and the condition remains misunderstood and undertreated.

UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an ...

A new study utilised data from the UK Biobank to shed light on a potential causal link between psoriasis and lung and breast ...

Armstrong, MD, MPH, chief of dermatology, UCLA, discusses clinical trial findings from the phase 2b study on zasocitinib.